Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.
about
Drug Pricing Evolution in Hepatitis CRapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis CA public health approach to hepatitis C control in low- and middle-income countries.Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.Development of risky varices in alcoholic cirrhosis with a well-maintained nutritional status.Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo TrialIntroduction and Utilization of High Priced HCV Medicines across Europe; Implications for the FutureEffective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Significance of HCV RNA monitoring in the era of new potent therapies.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Estimated generic prices for novel treatments for drug-resistant tuberculosis.Symptomatic Acute Hepatitis C Infection Following a Single Episode of Unprotected Sexual IntercourseA multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance.Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus.The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.Hepatitis C virus: Morphogenesis, infection and therapy.Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis CGeneric sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study
P2860
Q28550311-2076A164-063D-4A3A-AEAB-328A54E35B22Q34536041-274C3F3A-D5FC-4658-829E-AFF7E3D9DAA2Q35164735-54A511AF-3F08-4057-878B-EDDECDC558DFQ35501190-7CF31A62-C478-4375-B465-97729A4B7EAFQ36080449-440AA2B7-52A5-4C22-926B-81E3D58B0F63Q37056536-1E80F04D-E409-40E9-9B26-0FAC5166B0EFQ37135584-F5C8E36F-ED16-4A9A-ABC7-76416F39C366Q38755073-C4902525-FDA6-417E-AD3D-6A569EECEB6FQ38899447-367C8B86-CD93-4BB2-A212-3735FB24C58AQ39104215-62E909D0-EDAE-4059-9FB1-8E45FC03552EQ40377338-69D41757-A8EB-404A-AB6C-D4974A4995A2Q40412384-17AFA76C-E5EB-4194-9F01-24FD4F097F43Q40598773-989EC5CB-F7A8-488E-A96A-1925AB4A4C43Q40895917-5CE22F2D-562A-463D-9BDD-85FE612FF1E8Q42334786-F70D1F9A-1FFB-4B50-8E2F-2BD039A5CDCAQ52661702-CBCFD72E-1BDC-4104-8FAA-3A6A531B4B6EQ57071808-BBCC0B91-EC3B-4486-BCC4-0418091140DEQ57945693-2411A594-FF6C-4B7D-A126-242F12CDC405
P2860
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Minimum target prices for prod ...... s to combat hepatitis C virus.
@ast
Minimum target prices for prod ...... s to combat hepatitis C virus.
@en
Minimum target prices for prod ...... s to combat hepatitis C virus.
@nl
type
label
Minimum target prices for prod ...... s to combat hepatitis C virus.
@ast
Minimum target prices for prod ...... s to combat hepatitis C virus.
@en
Minimum target prices for prod ...... s to combat hepatitis C virus.
@nl
prefLabel
Minimum target prices for prod ...... s to combat hepatitis C virus.
@ast
Minimum target prices for prod ...... s to combat hepatitis C virus.
@en
Minimum target prices for prod ...... s to combat hepatitis C virus.
@nl
P2093
P2860
P356
P1433
P1476
Minimum target prices for prod ...... s to combat hepatitis C virus.
@en
P2093
Andrew Hill
Graham S Cooke
Joe Fortunak
Nathan Ford
Nikolien van de Ven
P2860
P304
P356
10.1002/HEP.27641
P407
P577
2015-02-09T00:00:00Z